Home › Acute Lymphoblastic Leukemia › North Carolina › Durham
Acute Lymphoblastic Leukemia clinical trials in Durham, NC
13 studies for Acute Lymphoblastic Leukemia are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecruitingPhase 1/2
- Duke University Medical Center, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Durham VA Medical Center, Durham
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
RecruitingHealthy volunteers welcome
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RecruitingPhase 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi away
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Registry of Older Patients With Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
A Study of Revumenib and Mezigdomide in People With Leukemia
RecruitingPhase 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi away
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi away
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
Pharmacokinetics of Drugs Administered to Children
RecruitingObservational study
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Acute Lymphoblastic Leukemia trials in other cities
- Houston, TX28 studies
- New York City, NY24 studies
- Seattle, WA21 studies
- Baldwin Park, CA21 studies
- Chicago, IL19 studies
- Atlanta, GA18 studies
- Memphis, TN16 studies
- Washington, DC16 studies
- Philadelphia, PA16 studies
- Boston, MA15 studies
- Los Angeles, CA14 studies
- Mountain View, CA13 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)59 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Metastatic Cancer33 studies
- Acute Myeloid Leukemia33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Chronic Lymphocytic Leukemia27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.